Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 1987Journal of Cardiovascular Pharmacology

Hemodynamic, Hormonal, and Pharmacokinetic Aspects of Treatment with Lisinopril in Congestive Heart Failure

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does lisinopril improve hemodynamic and hormonal parameters in patients with chronic stable congestive heart failure?

Population

24 patients with chronic stable congestive heart failure across two studies.

Comparison

Lisinopril. vs Baseline values and normal volunteers.

Design

Other

Follow-up

48 to 72 hours

Authors

KDKenneth DicksteinHeart Failure & Transplant

Discussion

Loading...

Member takes

Implication

May support hemodynamic relief in stable CHF; leaves open outcome benefits and needs randomized confirmation.

Structured PICO

Does lisinopril improve hemodynamic and hormonal parameters in patients with chronic stable congestive heart failure?

P
Population
24 patients with chronic stable congestive heart failure (CHF) across two studies (12 patients in the hemodynamic study, 12 hospitalized patients in the pharmacokinetic study).
I
Intervention
Lisinopril (single doses 1.25-10.0 mg on days 1 and 3 for the hemodynamic study; oral and intravenous administration for the pharmacokinetic study).
C
Comparator
Baseline values (for hemodynamic and hormonal parameters) and normal volunteers (for pharmacokinetic parameters).
O
Outcome
Acute hemodynamic (mean arterial pressure, mean pulmonary capillary wedge pressure, systemic vascular resistance, heart rate, cardiac index), hormonal (angiotensin I, angiotensin II, ACE activity, plasma renin activity, renin substrate, plasma aldosterone), and pharmacokinetic (serum drug concentration, urinary recovery) parameters.surrogate

Lisinopril demonstrates potent ACE inhibition and favorable hemodynamic effects lasting over 24 hours in patients with congestive heart failure, despite reduced oral absorption compared to normal volunteers.

Cite This Study

Kenneth Dickstein (1987) studied this question.

synapsesocial.com/papers/6a91a6aa6dcc5ddcb80210a4https://doi.org/10.1097/00005344-198700003-00019

Topics

Heart failureHFrEF treatment
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure.1989 · 22 citations
  2. 2ANTIHYPERTENSIVE AND HORMONAL EFFECTS OF LISINOPRIL, A NEW ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR IN PATIENTS WITH RENOVASCULAR HYPERTENSION.1986 · 8 citations
  3. 3Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.1996 · 47 citations
  4. 4Pharmacokinetics and Antihypertensive Effects of Lisinopril in Hypertensive Patients with Normal and Impaired Renal Function1990 · 18 citations
  5. 5Placebo-Controlled Study of Lisinopril in Congestive Heart Failure1987 · 90 citations